Active

Ampersand Capital Partners

Investor type

PE / VC

Founded

1988

AUM

$3 000 M

Location

Boston, Massachusetts, United States

Investment Ticket

$50-100 m

Investment Stage

Series B Series A Seed Late Stage (Series C+)

Region of investment

Europe North America Asia Australia and others
Investor profile last updated: 06 June, 2026

Profile

Founded in 1988, Ampersand is a middle-market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, Amsterdam and London, Ampersand leverages its unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors.

Consistent with our theme of increasing specialization as a source of differentiated performance, Ampersand’s Healthcare portfolio has been focused around several overlapping industry clusters where our multiple prior successes give us a competitive edge. Most of our portfolio companies have revenues between $10 and $200 million at the time of Ampersand’s investment. We typically invest between $10 and $200 million and years of operational expertise to drive each investment toward success.

Ampersand’s team has decades of operating experience in Healthcare companies and over 150 years of shared private equity experience. Our unusual combination of skills, including deep industry, technical, financial, operating, and transactional capabilities, make us a preferred partner for entrepreneurs because we can contribute to their success on multiple levels.

At our roots, we are company-builders, not investment managers. Our experience gives us empathy for our CEOs and helps us understand the challenges they face. This ability to identify, and contribute to, problem resolution makes us very effective in our companies.

Industry

MedTech Telecommunications Software Pharmaceuticals Medical Devices Marketing and Advertising Healthcare Services Life Sciences HealthTech Media and Entertainment Food and Beverage Foodtech

Ampersand Capital Partners Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
Ampersand 2014 Limited Partnership
Venture Capital (VC)
Healthcare Services
Marketing and Advertising
Media and Entertainment
Software
Telecommunications
HealthTech
Pre-seed
Seed
North America
Europe
$5-10 m
$110 M
March 2014
Ampersand 2018 Limited Partnership
Venture Capital (VC)
Food and Beverage
Foodtech
Healthcare Services
Marketing and Advertising
Media and Entertainment
Software
Telecommunications
HealthTech
Pre-seed
Seed
North America
Europe
$5-10 m
$450 M
March 2018
Ampersand 2022 Limited Partnership
Venture Capital (VC)
Food and Beverage
Foodtech
Healthcare Services
Marketing and Advertising
Media and Entertainment
HealthTech
Pre-seed
Seed
North America
Europe
$5-10 m
$1200 M
August 2022
Ampersand 2026 (“AMP-26”) Limited Partnership
Venture Capital (VC)
Food and Beverage
Foodtech
Healthcare Services
Marketing and Advertising
Media and Entertainment
Software
Telecommunications
HealthTech
Pre-seed
Seed
North America
Europe
$5-10 m
$1500 M
May 2026

Contacts

Name
Title
Email
avatar
Thomas Jager Vice President Business Development
Vice President Business Development
t•••@•••
avatar
Benoit Bouche Operating Partner
Operating Partner
b•••@•••
Upgrade to see contacts
avatar
mAZpshF0REGdNjoI mAZpshF0REGdNjoI
mAZpshF0REGdNjoI
avatar
mAZpshF0REGdNjoI mAZpshF0REGdNjoI
mAZpshF0REGdNjoI
avatar
mAZpshF0REGdNjoI mAZpshF0REGdNjoI
mAZpshF0REGdNjoI
Investment-team contacts for Ampersand Capital Partners — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Ampersand Capital Partners

Ampersand Capital Partners is a venture capital and private equity firm. It backs companies at Series B, Series A, Seed and Late Stage (Series C+), writing tickets of $50-100 m.
Ampersand Capital Partners is located in Boston, Massachusetts, United States.
Ampersand Capital Partners was founded in 1988.
Ampersand Capital Partners invests in companies and startups in MedTech, Telecommunications, Software, Pharmaceuticals, Medical Devices, Marketing and Advertising, Healthcare Services, Life Sciences, HealthTech, Media and Entertainment, Food and Beverage, Foodtech.
Ampersand Capital Partners invests in companies and startups in Europe, North America, Asia, Australia and others.
Ampersand Capital Partners invests in companies and startups at Series B, Series A, Seed, Late Stage (Series C+).
Ampersand Capital Partners usually invests $50-100 m on average.
Ampersand Capital Partners has around $3 000m assets under management.
Ampersand Capital Partners last fund was created/launched in 2026-05-28
Ampersand Capital Partners can be reached through its website ampersandcapital.com and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Ampersand Capital Partners — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Ampersand Capital Partners directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 06 June, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.